Other institutional investors and hedge funds have also recently modified their holdings of the company. Goodman Advisory Group LLC purchased a new position in Johnson & Johnson during the 2nd quarter valued at $39,000. TD Capital Management LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at $48,000. Cowa LLC purchased a new position in Johnson & Johnson during the 3rd quarter valued at $58,000. Adirondack Retirement Specialists Inc. purchased a new position in Johnson & Johnson during the 3rd quarter valued at $67,000. Finally, Heritage Wealth Management LLC bought a new stake in Johnson & Johnson during the 2nd quarter valued at $84,000. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Analyst Ratings Changes
A number of brokerages have weighed in on JNJ. SVB Leerink decreased their target price on Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research report on Friday, January 20th. Credit Suisse Group began coverage on Johnson & Johnson in a research report on Thursday, November 17th. They set a “neutral” rating and a $170.00 target price for the company. Raymond James decreased their target price on Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, October 19th. Sanford C. Bernstein decreased their target price on Johnson & Johnson from $194.00 to $190.00 in a research report on Wednesday, October 19th. Finally, Morgan Stanley lifted their target price on Johnson & Johnson from $176.00 to $180.00 and gave the company an “equal weight” rating in a research report on Wednesday, January 25th. Seven equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $175.71.
Insider Transactions at Johnson & Johnson
In other news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the sale, the chief accounting officer now owns 15,473 shares in the company, valued at $2,707,775. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In related news, CAO Robert J. Decker sold 16,928 shares of the company’s stock in a transaction dated Friday, November 18th. The stock was sold at an average price of $175.00, for a total value of $2,962,400.00. Following the completion of the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,707,775. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the company’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total value of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold 181,955 shares of company stock worth $32,081,502 over the last quarter. 0.35% of the stock is currently owned by insiders.
Johnson & Johnson Stock Down 0.4 %
Johnson & Johnson stock opened at $162.04 on Wednesday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The company has a market cap of $423.65 billion, a PE ratio of 24.04, a PEG ratio of 2.79 and a beta of 0.54. The business’s 50-day simple moving average is $172.25 and its two-hundred day simple moving average is $170.03.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 EPS for the quarter, topping analysts’ consensus estimates of $2.22 by $0.13. Johnson & Johnson had a return on equity of 35.94% and a net margin of 18.90%. The firm had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. During the same quarter in the prior year, the business earned $2.13 earnings per share. The company’s revenue was down 4.4% compared to the same quarter last year. Equities analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current year.
Johnson & Johnson Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st will be paid a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.79%. Johnson & Johnson’s payout ratio is 67.06%.
Johnson & Johnson Company Profile
(Get Rating)
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
Featured Stories
Receive News & Ratings for Johnson & Johnson Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Johnson & Johnson and related companies with MarketBeat.com’s FREE daily email newsletter.